HHS Logo U.S. Department of Health & Human Services Divider arrowNIH logo National Institutes of Health Alt desc
Skip Over Navigation Links
Steven Grant, M.D., in the laboratory

New Therapeutic Uses Awards

NCATS announced nearly $3 million to fund four drug repurposing projects aimed at finding therapies for type 2 diabetes, glioblastoma, acute myeloid leukemia and Chagas disease.

Work with Us

Learn more about how you can access funding and collaborate with the New Therapeutic Uses program.

Contact Christine Colvis, Ph.D.

Discovering New Therapeutic Uses for Existing Molecules

The New Therapeutic Uses program aims to improve the process of developing new treatments and cures for disease by finding new uses for assets that already have cleared several key steps along the development path (also known as drug repurposing). Learn more.

Find NCATS Programs & InitiativesAccess NCATS Expertise & Resources

About New Therapeutic Uses

Read more about the New Therapeutic Uses program and its progress.

Funding Information

Find out how to apply for New Therapeutic Uses funding.

Assets & Agreements

Access resources to get involved with the New Therapeutic Uses program.

New Therapeutic Uses Projects

Find details about ongoing New Therapeutic Uses projects.

New Therapeutic Uses and Drug Repurposing

Therapeutic development is a costly, complex and time-consuming process. The average length of time from target discovery to approval of a new drug is about 14 years. The failure rate during this process exceeds 95 percent, and the cost per successful drug can be $2 billion or more. The high therapeutic development failure rate means there are many existing, partially developed therapeutic candidates that could be repurposed for use in new disease indications. Bringing together the best assets from pharmaceutical companies with the best new ideas from academic researchers could produce new treatments much more quickly than starting from scratch. Learn more about the purpose of the New Therapeutic Uses program.